BERLIN— Pfizer Inc. and partner BioNTech SE said they are seeking approval from the European Union for their coronavirus vaccine.
The companies, which have already applied for authorization in the U.S. and U.K., submitted an application on Monday to the European Medicines Agency. That application was accepted on Tuesday by the regulator, the companies said.
The vaccine could be marketed later this month if the EMA concludes that data from trials show sufficient proof of the vaccine’s safety and efficiency, according to people familiar with the discussions.
The submission marked a milestone in the race to supply the world with a working vaccine to end the pandemic, said Ugur Sahin, the chief executive of BioNTech.
“We will continue to work with regulatory agencies around the world to enable the rapid distribution, should the vaccine receive the approval, contributing to the joint efforts to let the world heal and regain its normal pace of life,” Dr. Sahin said.
